atomoxetine hydrochloride has been researched along with Behavior Disorders in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 13 (59.09) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Geyer, MA; Phillips, AG; Robbins, TW | 1 |
| Bastiaens, L; Galus, J; Scott, O | 1 |
| Al-Enezi, N; AlShalabi, SR; Naguy, A | 1 |
| Dalsgaard, S; Nielsen, HS; Simonsen, M | 1 |
| Dahl, AA; Fredriksen, M; Haavik, J; Klungsøyr, O; Martinsen, EW; Peleikis, DE | 1 |
| Kirchheiner, J; Rodriguez-Antona, C | 1 |
| Chen, CY; Gerhard, T; Winterstein, AG | 1 |
| Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D | 1 |
| Calleja Pérez, B; Campos Díaz, Mdel R; Fernández-Jaén, A; Fernández-Mayoralas, DM; Muñoz Jareño, N | 1 |
| Terry, AV; Wilson, CA | 1 |
| Olfson, M | 1 |
| Burke, WJ; Daughton, JM; Kratochvil, CJ; Mayfield-Jorgensen, ML; Vaughan, BS | 1 |
| Brown, TE; Evans, SW; Gotlieb, EM; Knight, JR; Ross, EC; Shubiner, HH; Wender, EH; Wibbelsman, CJ; Wilens, T; Wolraich, ML | 1 |
| Johnston, JA; O'Hara, NN; Pohl, GM; Van Brunt, DL; Ye, W | 1 |
| Adler, LA; Biederman, J; Faraone, SV; Glatt, SJ; Michelson, D; Reimherr, FW; Spencer, TJ | 1 |
| Dewan, M; Faraone, SV; Kunwar, A | 1 |
| Goodman, DW | 1 |
| Egger, HL; Emslie, GJ; Gleason, MM; Greenhill, LL; Kowatch, RA; Lieberman, AF; Luby, JL; Owens, J; Scahill, LD; Scheeringa, MS; Stafford, B; Wise, B; Zeanah, CH | 1 |
| Barton, R | 1 |
| Coghill, D; Graham, J | 1 |
| Kratochvil, CJ; Vaughan, BS; Wetzel, MW | 1 |
| Biederman, J; Faraone, SV; Spencer, T; Wilens, TE | 1 |
11 review(s) available for atomoxetine hydrochloride and Behavior Disorders
| Article | Year |
|---|---|
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Depressive Disorder; Drug Discovery; Humans; Ketamine; Mental Disorders; Models, Animal; Nicotinic Agonists; Tobacco Use Disorder; Varenicline | 2018 |
New options in the pharmacological management of attention-deficit/hyperactivity disorder.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Mental Disorders; Propylamines; United States | 2004 |
Atomoxetine in the treatment of attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Mental Disorders; Propylamines | 2004 |
Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications.
Topics: Adolescent; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Case Management; Central Nervous System Stimulants; Child; Clonidine; Comorbidity; Continuity of Patient Care; Family Health; Female; Forecasting; Health Services Accessibility; Humans; Insurance Coverage; Intellectual Disability; Male; Mental Disorders; Patient Compliance; Propylamines; Puberty; Risk; Substance-Related Disorders | 2005 |
Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Comorbidity; Depressive Disorder, Major; Humans; Mental Disorders; Prevalence; Propylamines | 2007 |
The consequences of attention-deficit/hyperactivity disorder in adults.
Topics: Achievement; Adult; Age Factors; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Disease Progression; Female; Health Care Costs; Humans; Impulsive Behavior; Male; Mental Disorders; Methylphenidate; Propylamines; Quality of Life; Sex Distribution; Social Adjustment; Substance-Related Disorders | 2007 |
Psychopharmacological treatment for very young children: contexts and guidelines.
Topics: Algorithms; Amphetamines; Antidepressive Agents; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child Psychiatry; Child, Preschool; Drug Prescriptions; Humans; Mental Disorders; Methylphenidate; Propylamines; Psychopharmacology; Risperidone | 2007 |
Use of medication in children with psychiatric disorders.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child Psychiatry; Drug Prescriptions; Drug Utilization; Fluoxetine; Fluvoxamine; Health Policy; Humans; Melatonin; Mental Disorders; Methylphenidate; Needs Assessment; Patient Selection; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Psychotropic Drugs; Risperidone; Sertraline; United Kingdom | 2007 |
Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.
Topics: Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cardiovascular Diseases; Central Nervous System Stimulants; Clinical Trials as Topic; Growth Disorders; Humans; Mental Disorders; Nervous System Diseases; Propylamines | 2008 |
Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
Topics: Adult; Age Factors; Age of Onset; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; Cognitive Behavioral Therapy; Comorbidity; Humans; Mental Disorders; Methylphenidate; Propylamines; Psychology | 2008 |
Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Comorbidity; Desipramine; Humans; Mental Disorders; Methylphenidate; Propylamines; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Syndrome | 1998 |
3 trial(s) available for atomoxetine hydrochloride and Behavior Disorders
| Article | Year |
|---|---|
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Cognition Disorders; Comorbidity; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2010 |
Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Disorders; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Young Adult | 2010 |
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Health Status; Humans; Male; Mental Disorders; Neuropsychological Tests; Norepinephrine Plasma Membrane Transport Proteins; Placebos; Propylamines; Psychiatric Status Rating Scales; Risk Factors; Stress Disorders, Post-Traumatic; Treatment Outcome | 2006 |
8 other study(ies) available for atomoxetine hydrochloride and Behavior Disorders
| Article | Year |
|---|---|
Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.
Topics: Adrenergic Agents; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Guanfacine; Humans; Male; Mental Disorders; Nortriptyline; Outcome Assessment, Health Care; Prisoners; Retrospective Studies; Severity of Illness Index; Substance-Related Disorders | 2019 |
Atomoxetine in-focus!
Topics: Atomoxetine Hydrochloride; Humans; Mental Disorders; Neurodevelopmental Disorders; Neurotransmitter Uptake Inhibitors; Parkinson Disease | 2020 |
Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish registe
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Denmark; Dextroamphetamine; Female; Humans; Male; Mental Disorders; Methylphenidate; Practice Patterns, Physicians'; Prevalence; Propylamines; Registries | 2013 |
Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Topics: Adrenergic Uptake Inhibitors; Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Medication Adherence; Mental Disorders; Methylphenidate; Propylamines; Prospective Studies; Psychiatric Status Rating Scales; Stress, Psychological; Time Factors; Young Adult | 2014 |
Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Topics: Adult; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cytochrome P-450 CYP2D6; Genotype; Humans; Mental Disorders; Pharmacogenetics; Polymorphism, Genetic; Propylamines; Psychotropic Drugs; Treatment Outcome | 2009 |
Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Age Factors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Cohort Studies; Comorbidity; Demography; Family Practice; Female; Foster Home Care; Humans; Male; Mental Disorders; Practice Patterns, Physicians'; Propylamines; Psychotropic Drugs; Retrospective Studies; Sex Factors | 2009 |
Variable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Atomoxetine Hydrochloride; Behavior, Animal; Benzylidene Compounds; Disease Models, Animal; Female; Humans; Male; Maze Learning; Mental Disorders; Motor Activity; Nicotinic Agonists; Pregnancy; Prenatal Exposure Delayed Effects; Propylamines; Pyridines; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Risperidone; Social Behavior; Stress, Physiological | 2013 |
Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Databases, Factual; Female; Humans; Male; Managed Care Programs; Mental Disorders; Middle Aged; Propylamines; Retrospective Studies | 2006 |